Cell and Gene Therapy Catapult

Company

Related News

CGT Catapult establishes Technology Advisory Board for advanced therapy deployment

May 20, 2026

Cell and Gene Therapy Catapult has established a Technology Advisory Board to support technology deployment across advanced therapies. The board will focus on data, manufacturing, testing and patient pathways.

Review outlines non-clinical safety priorities for CRISPR-based gene therapies

May 12, 2026

A review in Genes & Diseases says robust non-clinical safety assessment is critical for CRISPR-based gene therapies. It highlights genotoxic, delivery, and immunological risks and recommends risk-based development programs.